Imugene Ltd (OTC:IUGNF) Financings

Imugene Ltd

Financings

RaiseDateIn US dollars
Convertible notes (New Notes)
Terms changed: convertible
Buyers: CVI Investments, Inc.
Nov 2, 2026
Convertible notes (TAR Notes)
Terms changed: convertible
Buyers: CVI Investments, Inc.
Nov 2, 2026
Private placement of fully paid ordinary shares
Closed: A$0.095 a share
Sep 1, 2026
Convertible notes (TAR Notes) and warrants
Closed: A$2.1M raised · Warrants at A$0.0664 for 60 months
Buyers: CVI Investments, Inc. ($2,100,000 worth of TAR Notes and 25,301,205 New Warrants)
Use of proceeds: Fund Cohort 2 and new Cohort 3 (BTKi) of its Phase 1b trial, plus general administrative and working capital
Aug 27, 2026US$1.49M
Private placement of new shares with attaching options
Announced: A$22.5M · A$0.33 a share · Warrants at A$0.43
Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26
Jul 16, 2025US$14.67M
Share purchase plan of new shares with attaching options
Announced: A$15M · A$0.33 a share · Warrants at A$0.43
Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26
Jul 16, 2025US$9.78M

Read by 6ix AI from the company's releases